婴儿肌肉骨骼疾病早期肉毒毒素注射的安全性与有效性系统综述
该系统综述评估了2岁以上患有骨科或神经相关肌肉骨骼疾病的婴儿接受肌肉内肉毒毒素注射(BTI)的安全性,分析了473例婴儿的数据,涵盖脑瘫、产科臂丛神经麻痹、马蹄内翻足和先天性斜颈。未报告任何可归因于BTI的严重不良事件,轻中度不良事件发生率为5%至25%。有效性证据初步且受限于研究数量少和证据等级低,需针对每种特定疾病开展更高等级研究。
要点
- 婴儿BTI未报告可归因的严重不良事件,轻中度不良事件率为5%至25%。
- 安全性风险更多与疾病严重程度和注射部位相关,而非毒素本身。
- 有效性证据初步,受限于研究数量少和证据等级低,需分病种深入研究。
核心结论
- 婴儿期肌肉内BTI的安全性特征与年长儿童相似,未报告可归因的严重不良事件。
- 有效性证据尚属初步,取决于具体疾病,且受限于研究数量少和证据等级低。
研究设计与样本
- 系统综述,检索PubMed、Cochrane Library、ScienceDirect、Google Scholar和Web of Science。
- 纳入研究由两名评价者独立筛选,使用PEDro量表评估随机对照试验、Downs and Black工具评估非随机研究,并采用改良Sackett量表确定证据等级。
主要发现
- 未报告任何可归因于BTI的严重不良事件。
- 报告的轻中度不良事件发生率范围为5%至25%。
- 有效性结果初步,取决于病理类型,且受研究数量少和证据等级低限制。
关键数值与推荐
- 轻中度不良事件发生率范围为5%至25%。
临床怎么用
- BTI已在该年龄组作为早期治疗广泛使用,安全性特征与年长儿童相似。
- 风险可能更多与疾病严重程度和注射部位相关,而非毒素本身。
- 有效性证据尚不充分,临床决策需结合具体疾病并期待更高等级研究。
局限性
- 有效性证据受限于研究数量少和证据等级低。
- 结果关于有效性为初步,取决于病理类型。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To report current evidence regarding the safety of intramuscular botulinum toxin injection (BTI) in children with orthopedic- and neurologic-related musculoskeletal disorders >2 years of age. DATA SOURCES: PubMed, Cochrane Library, and ScienceDirect, Google Scholar, and Web of Science. STUDY SELECTION: Two reviewers independently selected studies based on predetermined inclusion criteria. DATA EXTRACTION: Data relating to the aim were extracted. Methodologic quality was graded independently by 2 reviewers using the Physiotherapy Evidence Database scale for randomized controlled trials (RCTs) and the Downs and Black evaluation tool for non-RCTs. Level of evidence was determined using the modified Sackett scale. DATA SYNTHESIS: Data of 473 infants were analyzed. Fifty-five infants had cerebral palsy, 112 had obstetric brachial plexus palsy, 257 had clubfoot, and 44 had congenital torticollis. No studies reported any severe adverse event that could be attributed to the BTI. The rate of mild to moderate adverse events reported varied from 5% to 25%. Results regarding efficacy were preliminary, dependent on the pathology, and limited by the small number of studies and their low levels of evidence. CONCLUSIONS: BTI is already widely used as an early treatment for this age group. The safety profile of BTI in infants appears similar to that of older children and risks appear more related to the severity of the pathology and the location of the injections than to the toxin itself. Regarding effectiveness, other studies with higher levels of evidence should be carried out for each specific pathology.
引用
- Bourseul JS, Molina A, Lintanf M, et al. Early Botulinum Toxin Injections in Infants With Musculoskeletal Disorders: A Systematic Review of Safety and Effectiveness. Arch Phys Med Rehabil. 2017. PMID: 29288113. doi:10.1016/j.apmr.2017.11.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。